We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
-0.05%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$381M
AUM Growth
-$49.9M
(-12%)
Cap. Flow
-$22.9M
Cap. Flow
% of AUM
-6%
Top 10 Holdings %
Top 10 Hldgs %
22.14%
Holding
176
New
41
Increased
28
Reduced
15
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keros Therapeutics
KROS
|
+$4.48M |
| 2 |
Flux Power
FLUX
|
+$4.41M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$4.41M |
| 4 |
AFMD
Affimed
AFMD
|
+$4.38M |
| 5 |
Celldex Therapeutics
CLDX
|
+$4.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palisade Bio
PALI
|
+$7.43M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$7.11M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$6.25M |
| 4 |
EPIX
ESSA Pharma
EPIX
|
+$6.1M |
| 5 |
electroCore
ECOR
|
+$5.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.97% |
| 2 | Financials | 5.73% |
| 3 | Technology | 2.04% |
| 4 | Industrials | 1.47% |
| 5 | Communication Services | 1.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
POL.WS
1
DELISTED
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
| $11.6M | 3.03% |
6,886,600
| – | – |
|
|
BLU
2
DELISTED
BELLUS Health Inc.
BLU
| $11M | 2.88% |
1,788,789
| – | – |
|
|
3
Celldex Therapeutics
CLDX
$2.79B
| $9.99M | 2.62% |
185,000
+91,884
| +99% | +$4.31M |
|
|
CTIC
4
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $9.77M | 2.56% |
3,313,000
-365,677
| -10% | -$996K |
|
5
Aldeyra Therapeutics
ALDX
$95.3M
| $7.59M | 1.99% |
864,020
| – | – |
|
6
Lantheus
LNTH
$6.68B
| $7.45M | 1.95% |
290,000
+49,934
| +21% | +$1.3M |
|
7
Xtant Medical Holdings
XTNT
$59.7M
| $6.94M | 1.82% |
6,254,458
-2,038,144
| -25% | -$2.65M |
|
8
Verastem
VSTM
$547M
| $6.94M | 1.82% |
187,750
+44,784
| +31% | +$1.65M |
|
9
Cerus
CERS
$585M
| $6.7M | 1.76% |
1,100,000
+285,672
| +35% | +$1.67M |
|
10
Curis
CRIS
$9.41M
| $6.49M | 1.7% |
2,073
| – | – |
|
11
CytomX Therapeutics
CTMX
$701M
| $6.28M | 1.65% |
1,233,642
+371,225
| +43% | +$1.99M |
|
12
Immatics
IMTX
$1.19B
| $6.23M | 1.63% |
478,987
+134,429
| +39% | +$1.71M |
|
13
Protagonist Therapeutics
PTGX
$8.8B
| $6.13M | 1.61% |
346,000
+63,555
| +23% | +$2.71M |
|
14
Arcutis Biotherapeutics
ARQT
$3.55B
| $6.09M | 1.6% |
255,000
+23,686
| +10% | +$540K |
|
15
Inspire Medical Systems
INSP
$1.5B
| $6.05M | 1.59% |
26,000
+5,345
| +26% | +$1.12M |
|
|
NVRO
16
DELISTED
NEVRO CORP.
NVRO
| $5.93M | 1.56% |
51,000
+24,100
| +90% | +$3.15M |
|
|
KDNY
17
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $5.93M | 1.56% |
465,000
+48,433
| +12% | +$637K |
|
18
CareDx
CDNA
$1.85B
| $5.7M | 1.5% |
90,000
+26,566
| +42% | +$2.02M |
|
|
SYRS
19
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $5.69M | 1.49% |
127,241
+19,547
| +18% | +$954K |
|
20
Insmed
INSM
$22.6B
| $5.6M | 1.47% |
203,354
| – | – |
|
21
Ocular Therapeutix
OCUL
$1.85B
| $5.56M | 1.46% |
556,000
+299,848
| +117% | +$3.37M |
|
|
RNAM
22
DELISTED
Avidity Biosciences
RNAM
| $5.54M | 1.45% |
225,000
+36,400
| +19% | +$791K |
|
|
APLS
23
PUT
DELISTED
Apellis Pharmaceuticals
APLS
| $5.49M | 1.44% |
+166,700
| New | +$9.37M |
|
|
KLR
24
DELISTED
Kaleyra, Inc.
KLR
| $5.33M | 1.4% |
138,455
-44,402
| -24% | -$1.75M |
|
|
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.33M | 1.4% |
328,101
-574,532
| -64% | -$6.25M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Altium Capital Management held 176 positions worth $381M, down 12% from $431M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Altium Capital Management withdrew a net $22.9M in Q3 2021, closing 51 positions and reducing 15 holdings. Its most notable exit was Palisade Bio, an estimated $7.43M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Technology.
Against the trend, Altium Capital Management opened a new position in Keros Therapeutics worth $4.99M.
- Altium Capital Management's largest Q3 2021 buy was Keros Therapeutics: 126,000 shares worth $4.99M.
- Altium Capital Management added most to Celldex Therapeutics in Q3 2021, an estimated $4.31M increase.
- Altium Capital Management's biggest Q3 2021 reduction was Crinetics Pharmaceuticals, cutting an estimated $7.11M.
- Altium Capital Management fully exited Palisade Bio in Q3 2021, selling an estimated $7.43M.
- Altium Capital Management's ten largest holdings make up 22% of its $381M portfolio in Q3 2021.
- Altium Capital Management opened 41 new positions and closed 51 in Q3 2021.
- Altium Capital Management's portfolio value fell 12% quarter-over-quarter to $381M.
Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.